Kiora Pharmaceuticals (NASDAQ: KPRX) announced preclinical data demonstrating that its novel ion channel modulator, KIO-300, significantly suppressed seizure-associated electrophysiological activity in an ex vivo temporal lobe epilepsy (TLE) model. The findings were presented in a poster at the Epilepsy Foundation Pipeline Conference taking place June 18-19, 2026, in Leesburg, VA. The data marks a potential expansion for Kiora's ion channel platform, which is currently being evaluated in a Phase 2 clinical trial for vision restoration in retinitis pigmentosa.
KIO-300 is the active pharmaceutical ingredient of KIO-301, the company's lead candidate for restoring vision in patients with inherited retinal degenerations. The new preclinical results indicate that the compound may also hold promise for neurological conditions such as epilepsy. In the study, KIO-300 demonstrated a significant reduction in epileptiform activity, which is the abnormal electrical activity in the brain that characterizes seizures. This suggests that the ion channel modulator could potentially be developed as a treatment for temporal lobe epilepsy, one of the most common and treatment-resistant forms of epilepsy.
The implications of this announcement are twofold. First, it validates the broader therapeutic potential of Kiora's ion channel modulator platform beyond ophthalmology. If successful in clinical development, KIO-300 could address a significant unmet need in epilepsy, where approximately one-third of patients do not achieve adequate seizure control with existing medications. Second, it provides a potential pipeline expansion opportunity for Kiora, which is currently focused on retinal diseases. The company's platform could generate multiple drug candidates targeting different indications, potentially increasing its commercial value and reducing risk through diversification.
For patients and the epilepsy community, these findings offer hope for new treatment options. Temporal lobe epilepsy is often difficult to manage, and many patients experience debilitating seizures that impact quality of life. A novel mechanism of action, such as ion channel modulation, could provide an alternative for those who have not responded to conventional therapies. However, it is important to note that these results are preclinical, and further studies are needed to confirm safety and efficacy in humans.
The Epilepsy Foundation Pipeline Conference is a key venue for presenting emerging therapies, and Kiora's selection to present underscores the interest in innovative approaches to epilepsy treatment. The company plans to continue evaluating KIO-300 in additional preclinical models and may consider advancing it into clinical trials if the data remain supportive.
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing advanced therapies for retinal disease, with a focus on small molecules that target critical pathways. KIO-301 is being developed for retinitis pigmentosa and has potential to expand into choroideremia and Stargardt disease. KIO-104 is a next-generation non-steroidal immunomodulator for macular edema. More information is available at www.kiorapharma.com.
